Company Filing History:
1 out of 378 
1 out of 721 
Years Active: 2013-2017
Title: The Innovative Journey of Inventor Kerstin Baral
Introduction
Kerstin Baral, an accomplished inventor based in Mannheim, Germany, has made significant contributions to the field of biotechnology. With a focus on developing innovative antibodies, her work is at the forefront of medical advancement, directly impacting the treatment of various diseases.
Latest Patents
Kerstin holds two noteworthy patents, both centered around antibodies that target tumor necrosis factor alpha (TNFα). These patents detail the creation of antibodies, antigen-binding portions, and their derivatives that demonstrate high affinity for TNFα. Furthermore, the patents encompass nucleic acids encoding these antibodies, including complementary nucleic acids, as well as the vectors and host cells containing such nucleic acids. This innovation showcases her expertise and the potential clinical applications of her research in therapeutic contexts.
Career Highlights
Throughout her career, Kerstin has worked with prominent companies renowned for their advancements in pharmaceuticals and intellectual property. Notable among them are Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. Her experience in these organizations has strengthened her expertise in the development and protection of biopharmaceutical innovations, contributing to her success as an inventor.
Collaborations
Kerstin’s professional journey has been enriched by collaborating with esteemed colleagues in the field, including Christian Votsmeier and Uwe Gritzan. These partnerships not only enhance the breadth of her research but also amplify the impact of her innovations in the scientific community.
Conclusion
Kerstin Baral exemplifies the innovative spirit of modern inventors, particularly in the biotechnology sector. With her two patents focusing on antibodies for TNFα, she continues to pave the way for future research and therapeutic solutions. Her collaborations and experience in leading companies highlight her valuable contributions to the field and her dedication to advancing medical science.